media – Page 615 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Oral Drug Beats Interferon in First Pediatric MS Trial

In the first randomized controlled trial in pediatric multiple sclerosis, fingolimod (Gilenya) significantly cut relapses compared with interferon beta-1a (Avonex), researchers reported here.
- Source: medpagetoday
- 649
- October 30, 2017
beta-1a Clinical Trials interferon multiple sclerosis pediatric
Surgeon diagnoses his own cancer with an iPhone

US vascular surgeon John Martin found cancerous cells in his own neck while testing a portable ultrasound device called Butterfly iQ.
- Source: cnet
- 522
- October 30, 2017
Butterfly iQ cancer Market Views ultrasound
Alzheimer’s–Brain’s protective mechanism revealed

Buildups of "clumpy" proteins in the brain are well-known hallmarks of Alzheimer's, but not everyone who has them goes on to develop this neurodegenerative disease. Why is that? New research investigates.
- Source: medicalnewstoday
- 625
- October 30, 2017
Alzheimer's dendritic spines neurodegenerative Researches
Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients

Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in serving patients with rare diseases, announced today that the European Commission (EC) has approved a label extension granting a new indication for FIRAZYR® (icatibant injection), broadening its use to adolescents and children aged 2 years and older, with hereditary angioedema (HAE) caused by C1-esterase-inhibitor (C1-INH) deficiency. FIRAZYR has been approved in the European Union (EU) since 2008 for symptomatic treatment of acute attacks of HAE in adults with C1-INH deficiency.
- Source: finance.yahoo
- 537
- October 30, 2017
EC FIRAZYR® HAE Shire
US FDA finalises new guidelines for medical device development

The US Food and Drug Administration (FDA) has announced new measures to promote medical device innovation and provide patients with fast access to beneficial technologies.
- Source: medicaldevice-network
- 464
- October 30, 2017
FDA medical device
Why Are There No Repeat Orders?

Four Reasons to Explain Why Repeat Orders Never Come
- Source: Ddu
- 612
- October 27, 2017
clients Ddu College inquiry orders
Ddu College–Market Report of Coronary Stents

Coronary heart disease is a common illness of cardiovascular disease which is treated mainly through medicines, coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). Remarkably, PCI is preferable to both clinicians and patients for its short treatment course, small wound and significant therapeutic effects: doctors can use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque without thoracotomy. Today, Ddu is going to share the market report of coronary stent with you.
- Source: Ddu
- 1,093
- October 27, 2017
cardiovascular coronary stent Ddu College
Skin may regulate blood pressure, study finds

When it comes to high blood pressure, a lack of exercise and a poor diet are often the primary suspects. A new study, however, finds that our skin may play a significant role in the development of the condition.
- Source: medicalnewstoday
- 851
- October 27, 2017
heart attacks high blood pressure oxygen Researches stroke
Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG

Biogen (NASDAQ: BIIB) announced that it has increased the profit potential on aducanumab, its Phase 3 investigational treatment for early Alzheimer’s disease, by reducing the potential royalty payment on potential commercial sales of aducanumab to Neurimmune Holding AG. In exchange for a 15 percent reduction in the previously negotiated royalty rates, Biogen agreed to make a one-time $150 million payment to Neurimmune Holding AG.
- Source: media.biogen
- 464
- October 27, 2017
aducanumab Alzheimer's disease Biogen
Not Enough Participants

Patient participation in clinical trials for cancer patients has been in decline. Researchers determine the barriers prohibiting participation.
- Source: medicalnewsbulletin
- 705
- October 27, 2017
cancer Clinical Trials

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.